pentylenetetrazole has been researched along with Brain Infarction in 1 studies
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.
pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.
Brain Infarction: Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Finally, we showed that kainate induced seizures and glycemia were not modified by spadin treatments." | 1.38 | Spadin as a new antidepressant: absence of TREK-1-related side effects. ( Borsotto, M; Coppola, T; Gandin, C; Heurteaux, C; Labbal, F; Mazella, J; Moha Ou Maati, H; Veyssiere, J; Widmann, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moha Ou Maati, H | 1 |
| Veyssiere, J | 1 |
| Labbal, F | 1 |
| Coppola, T | 1 |
| Gandin, C | 1 |
| Widmann, C | 1 |
| Mazella, J | 1 |
| Heurteaux, C | 1 |
| Borsotto, M | 1 |
1 other study available for pentylenetetrazole and Brain Infarction
| Article | Year |
|---|---|
Spadin as a new antidepressant: absence of TREK-1-related side effects.
Topics: Animals; Antidepressive Agents; Biophysical Phenomena; Blood Glucose; Brain Infarction; CD8 Antigens | 2012 |